Established Cardiovascular Disease: When Medication Isn't Enough

What Residual Cardiovascular Risk Means and Why It Persists

Residual cardiovascular risk is the probability of a second heart attack, stroke, or cardiovascular death that remains after a patient is treated with guideline-directed medical therapy (GDMT). This is not a small number. A 2019 analysis published in the European Heart Journal estimated that patients with prior atherosclerotic cardiovascular disease (ASCVD) events retain a 5 to 10% annual MACE rate despite statin therapy, antiplatelets, and blood pressure control [1].

Why does risk persist? Atherosclerosis is driven by dozens of overlapping mechanisms. Statins lower LDL-C and stabilize plaques, but they do not address inflammatory burden measured by high-sensitivity C-reactive protein (hs-CRP), nor do they correct insulin resistance, visceral adiposity, or elevated lipoprotein(a). The CANTOS trial (N=10,061) demonstrated that targeting interleukin-1β with canakinumab reduced recurrent CV events by 15% independently of lipid lowering, proving that inflammation itself is a treatable driver of residual risk [2]. Patients who achieve both an LDL-C below 70 mg/dL and an hs-CRP below 2 mg/L have markedly better outcomes than those who reach only one of these targets [3].

Excess body weight compounds the problem. Visceral fat secretes proinflammatory adipokines, worsens insulin resistance, and raises blood pressure through sympathetic activation. A body mass index (BMI) above 30 kg/m² increases the odds of recurrent MI by approximately 25% in secondary-prevention cohorts [4]. These interrelated mechanisms explain why a pill-only strategy leaves a measurable gap in protection.

GLP-1 Receptor Agonists: The SELECT Trial and Beyond

Semaglutide 2.4 mg weekly became the first weight-management drug shown to reduce hard cardiovascular endpoints in patients without diabetes who already had established CVD. The point is simple: weight loss done the right way saves lives.

The SELECT trial (N=17,604) randomized adults aged 45 and older with a BMI of 27 or above and established atherosclerotic cardiovascular disease (prior MI, stroke, or symptomatic peripheral arterial disease) to subcutaneous semaglutide 2.4 mg or placebo [5]. At a median follow-up of 39.8 months, semaglutide reduced the primary composite endpoint of cardiovascular death, nonfatal MI, or nonfatal stroke by 20% (hazard ratio 0.80 to 95% CI 0.72 to 0.90, P<0.001) [5]. All-cause mortality showed a numerical reduction of 19%, and confirmed cardiovascular death fell by 15%.

The mechanism is not weight loss alone. Participants on semaglutide lost a mean of 9.4% body weight versus 0.9% on placebo, but mediation analyses suggest that weight loss accounted for only about 40% of the MACE benefit [5]. Anti-inflammatory effects (hs-CRP dropped by 37.8% from baseline), reductions in waist circumference, improvements in glycemic parameters, and direct vascular actions of GLP-1 receptor activation all appear to contribute.

Dr. A. Michael Lincoff, the lead investigator of SELECT and chair of cardiovascular medicine at the Cleveland Clinic, stated: "These findings indicate that treatment of obesity itself, in addition to its risk factors, should be part of a comprehensive secondary-prevention strategy for patients with established cardiovascular disease" [5].

The 2023 AHA/ACC guidelines now include GLP-1 receptor agonists as a Class IIa recommendation for patients with ASCVD and overweight or obesity who need additional cardiovascular risk reduction beyond standard therapy [6]. Liraglutide (LEADER trial) and dulaglutide (REWIND trial) showed similar directional MACE benefits in populations with type 2 diabetes [7][8], but SELECT was the first trial to demonstrate benefit in a non-diabetic, secondary-prevention population selected specifically for adiposity.

Structured Exercise and Cardiac Rehabilitation

Cardiac rehabilitation (CR) is one of the most effective and most underused interventions in secondary prevention. Only about 24% of eligible patients in the United States complete a CR program after an MI or revascularization procedure [9]. That gap represents thousands of preventable deaths each year.

A Cochrane review of 63 trials (N=14,486) found that exercise-based CR reduced cardiovascular mortality by 26% (risk ratio 0.74 to 95% CI 0.64 to 0.86) and hospital readmissions by 18% compared with usual care [10]. The benefits were consistent regardless of type of heart disease, age, or sex. Programs that included psychosocial components showed slightly larger reductions in all-cause mortality.

Exercise capacity itself is a dose-dependent predictor of survival. Each 1-MET improvement in cardiorespiratory fitness reduces cardiovascular mortality by approximately 12% [11]. For patients with established CVD, the 2018 Physical Activity Guidelines Advisory Committee reported that 150 to 300 minutes per week of moderate-intensity aerobic activity produces the greatest marginal benefit, with high-intensity interval training (HIIT) showing comparable or superior gains in VO₂ max in head-to-head trials [12].

A practical starting prescription for a post-MI patient might look like this:

• Weeks 1 to 4: supervised walking, 20 to 30 minutes, 3 to 5 days per week, at 40 to 50% of heart rate reserve (HRR)
• Weeks 5 to 12: progress to 30 to 45 minutes at 50 to 70% HRR; add resistance training 2 days per week at 40 to 60% of 1-rep max
• Week 13 onward: transition to a maintenance program at 60 to 80% HRR, 5 days per week, adding HIIT intervals if tolerated and cleared by a cardiologist

Resistance training, once discouraged after cardiac events, is now endorsed by the AHA as safe and beneficial when initiated at low loads with gradual progression [13]. Two to three sessions per week targeting major muscle groups improves insulin sensitivity, reduces resting blood pressure by 3 to 5 mmHg, and decreases visceral fat even without significant changes on the scale.

Dietary Patterns That Reduce Recurrent Events

The question is not whether diet matters for secondary prevention. It does. The question is which dietary pattern has the strongest trial evidence.

The PREDIMED trial (N=7,447) randomized participants at high cardiovascular risk (though not all with established CVD) to a Mediterranean diet supplemented with extra-virgin olive oil, a Mediterranean diet supplemented with mixed nuts, or a control low-fat diet [14]. At a median of 4.8 years, the olive-oil arm reduced major cardiovascular events by 30% (HR 0.70 to 95% CI 0.54 to 0.92) and the mixed-nuts arm by 28% (HR 0.72 to 95% CI 0.54 to 0.96) compared with the control group [14].

The CORDIOPREV trial focused specifically on patients with established coronary heart disease (N=1,002) and found that a Mediterranean diet reduced major cardiovascular events by 28% compared with a low-fat diet over 7 years of follow-up (HR 0.72 to 95% CI 0.54 to 0.96, P=0.025) [15]. This was the first long-term RCT to test the Mediterranean diet exclusively in a secondary-prevention population.

The 2021 ESC Guidelines on cardiovascular disease prevention recommend a Mediterranean or similar plant-rich dietary pattern as a Class I, Level A recommendation, stating: "A Mediterranean-type diet reduces the risk of cardiovascular events and should be encouraged for all patients with established CVD" [16].

Key components that carry the strongest mechanistic and epidemiological support include:

• Extra-virgin olive oil (at least 4 tablespoons/day): rich in oleocanthal, which inhibits COX-1 and COX-2 pathways similarly to low-dose ibuprofen
• Fatty fish (2 to 3 servings/week): the REDUCE-IT trial showed that 4 g/day of icosapent ethyl (purified EPA) reduced ischemic events by 25% in statin-treated patients with elevated triglycerides (HR 0.75, P<0.001) [17]
• Nuts (30 g/day): a pooled analysis of the Nurses' Health Study and Health Professionals Follow-up Study found a 20% lower CHD mortality with 5+ servings per week [18]
• Fiber (25 to 30 g/day from whole grains, legumes, vegetables): each 7 g/day increase in fiber intake is associated with a 9% lower risk of coronary events [19]
• Sodium restriction (<2 to 300 mg/day, ideally <1 to 500 mg for hypertensive patients): the DASH-Sodium trial showed incremental blood pressure reductions with each level of sodium restriction [20]

Ultra-processed foods, sugar-sweetened beverages, and processed red meats should be minimized. A 10% increase in ultra-processed food consumption has been linked to a 12% increase in cardiovascular disease incidence in prospective cohort data [21].

Smoking Cessation: The Single Largest Modifiable Risk Factor

Quitting smoking after an MI reduces the risk of a second event by approximately 36% within 2 years, a magnitude of benefit comparable to statin therapy [22]. No other single lifestyle change delivers this large an effect this quickly.

Combination pharmacotherapy (varenicline plus nicotine replacement therapy) doubles long-term quit rates compared with monotherapy [23]. The EAGLES trial (N=8,144) confirmed that varenicline carries no excess neuropsychiatric risk compared with placebo, nicotine patch, or bupropion, even in patients with stable psychiatric conditions [24]. For patients who are not ready to quit entirely, a harm-reduction approach using nicotine replacement to reduce cigarettes per day by at least 50% has been shown to increase eventual complete cessation rates [23].

Electronic cigarettes remain controversial. The 2024 AHA Scientific Statement notes insufficient long-term safety data to recommend e-cigarettes as a first-line cessation tool but acknowledges that they may be considered for adults who have failed FDA-approved therapies, provided the goal remains complete nicotine cessation [25].

Blood Pressure, Lipids, and Emerging Targets

Aggressive risk-factor control magnifies the benefit of every lifestyle change. The targets matter.

Blood pressure: The 2017 ACC/AHA guidelines lowered the treatment target for secondary prevention to below 130/80 mmHg [26]. The SPRINT trial (N=9,361) showed that intensive blood pressure control (systolic <120 mmHg) reduced the composite cardiovascular endpoint by 25% and all-cause mortality by 27% compared with standard control (systolic <140 mmHg), though hypotension and acute kidney injury were more common in the intensive arm [27].

LDL-C: The 2019 ESC/EAS guidelines recommend an LDL-C target below 55 mg/dL and at least a 50% reduction from baseline for patients at very high risk, including those with established ASCVD [28]. If maximally tolerated statin therapy plus ezetimibe does not reach this target, PCSK9 inhibitors (evolocumab, alirocumab) are recommended. The FOURIER trial (N=27,564) demonstrated that evolocumab reduced the composite of cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization by 15% (HR 0.85, P<0.001) [29].

Lipoprotein(a): Approximately 20% of the general population carries genetically elevated Lp(a) above 50 mg/dL, a level associated with a 1.5- to 2-fold increase in ASCVD risk [30]. Current medications do not meaningfully lower Lp(a). Pelacarsen, an antisense oligonucleotide targeting hepatic Lp(a) production, reduced Lp(a) by approximately 80% in a phase 2 trial [31]. The phase 3 Lp(a)HORIZON trial (N=8,323) is expected to report in 2026, and a positive result would create the first treatment option for this common, undertreated risk factor.

Inflammation: For patients with persistent hs-CRP above 2 mg/L despite optimal therapy, low-dose colchicine (0.5 mg daily) is an option. The COLCOT trial (N=4,745) showed that colchicine started within 30 days of an MI reduced the composite of cardiovascular death, resuscitated cardiac arrest, MI, stroke, or urgent hospitalization for angina by 23% (HR 0.77 to 95% CI 0.61 to 0.96, P=0.02) [32]. The LoDoCo2 trial (N=5,522) confirmed similar benefits in patients with chronic coronary disease [33].

Stress, Sleep, and Psychosocial Health

Depression affects 20 to 30% of post-MI patients and independently doubles the risk of recurrent events and mortality over 2 years [34]. Screening with the PHQ-9 at each follow-up visit is recommended by the AHA as a Class I recommendation [35]. Treatment with SSRIs (sertraline and citalopram have the most safety data in cardiac populations) and cognitive behavioral therapy both reduce depressive symptoms, though evidence for direct MACE reduction from treating depression remains mixed.

Sleep is another underappreciated variable. Obstructive sleep apnea (OSA) affects 40 to 60% of patients with established CVD and is associated with resistant hypertension, atrial fibrillation, and recurrent ischemic events [36]. The apnea-hypopnea index (AHI) should be assessed in any patient with refractory hypertension, excessive daytime sleepiness, or witnessed apneas. While the SAVE trial (N=2,717) failed to show that CPAP alone reduced MACE in patients with moderate-to-severe OSA and established CVD, adherence was poor (mean 3.3 hours/night), and subgroup analyses suggested benefit in patients using CPAP for 4 or more hours nightly [37].

Practical sleep hygiene targets for cardiac patients: 7 to 8 hours of sleep per night, consistent sleep and wake times within a 30-minute window, and room temperature between 65 and 68°F. Short sleep (<6 hours) and long sleep (>9 hours) are both associated with increased cardiovascular mortality in a U-shaped dose-response relationship [38].

Building a Comprehensive Secondary-Prevention Plan

The evidence points clearly to a layered approach. Medication alone leaves too much risk on the table. Lifestyle alone is insufficient when plaques are already unstable and lipids are dangerously high.

The practical framework for a patient with established ASCVD and a BMI of 30 who has already had a stent placement looks like this:

1. Confirm GDMT optimization: high-intensity statin, antiplatelet (aspirin or P2Y12 inhibitor), ACE inhibitor or ARB, beta-blocker if post-MI with reduced ejection fraction. Verify LDL-C is below 55 mg/dL; if not, add ezetimibe, then consider PCSK9 inhibitor.
2. Address weight: if BMI is 27 or above, discuss GLP-1 RA therapy (semaglutide 2.4 mg weekly) in the context of the SELECT trial data showing 20% MACE reduction [5].
3. Enroll in cardiac rehab: target completion of 36 sessions; each session attended is associated with a 1% relative reduction in mortality [10].
4. Adopt a Mediterranean dietary pattern: prioritize extra-virgin olive oil, fatty fish, nuts, legumes, and whole grains. Limit sodium to below 2 to 300 mg/day.
5. Quit smoking: offer varenicline plus NRT combination as first-line pharmacotherapy.
6. Screen for depression and sleep apnea: PHQ-9 at each visit; sleep study if clinical suspicion for OSA.
7. Check emerging biomarkers: measure Lp(a) at least once; check hs-CRP to guide anti-inflammatory therapy decisions.

The difference between a patient on four medications alone and a patient on the same four medications plus cardiac rehab, a Mediterranean diet, 9% weight loss on a GLP-1 RA, and smoking cessation could be a 50 to 60% cumulative reduction in recurrent MACE events over 5 years, compared with approximately 25 to 30% from medications alone [5][10][14][22]. These numbers are additive because the interventions target different pathways: lipid burden, inflammation, thrombosis, hemodynamics, adiposity, and autonomic tone.

The first lab check after initiating this plan should occur at 12 weeks to reassess LDL-C, hs-CRP, HbA1c, and triglycerides, with a repeat echocardiogram at 6 months if baseline ejection fraction was below 50%.